
Dewpoint Therapeutics: A global biotech firm developing a drug platform targeting biomolecular condensates.
Dewpoint Therapeutics, founded with a daring vision to revolutionize drug discovery, focuses on developing a platform that targets biomolecular condensates. These condensates are cellular structures that play a crucial role in various diseases. The company aims to harness this novel biology to create therapies for a range of conditions, thereby addressing unmet medical needs. Dewpoint Therapeutics serves a global market, offering innovative solutions that could transform the landscape of biotech and pharmaceutical industries.
Notable figures affiliated with Dewpoint Therapeutics include its visionary founders and a team of leading scientists in the field of cell biology. The company has attracted significant investment from prominent venture capital firms, underscoring its potential impact. Key achievements include the development of a robust pipeline of therapeutic candidates and numerous publications in high-impact scientific journals. Dewpoint Therapeutics is poised to make substantial contributions to the biotech industry by advancing our understanding of cellular biology and developing groundbreaking treatments.
Companies similar to Dewpoint Therapeutics include Faze Medicines, Transition Bio, Nereid Therapeutics and Triana Biomedicines.
Dewpoint Therapeutics was founded in 2018.
Dewpoint Therapeutics' headquarters is located in Boston, MA, US.
Dewpoint Therapeutics' most recent funding round was for $150M (USD) in February 2022.
As of Feb 3, 2022, Dewpoint Therapeutics has disclosed funding of $287M (USD). Undisclosed round amounts are excluded.
Dewpoint Therapeutics has 161 employees as of Feb 5, 2024.
Triana Biomedicines
trianabio.com